SavedAdd your journal

Journals / Türk Patoloji Dergisi / 2022 / Cilt: 38 - Sayı: 3

Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called “SET Morphology” and Progesterone Receptor Status

Halit UNER
Metin DEMIR
Dincer GOKSULUK
Ayse KARS
Meral UNER
Alp USUBUTUN
Pages
240–250
Publication Date
2022-11-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival (OS) of ovarian carcinoma in SET-predominant tumors (n=60) was 81 months, while for tumors with SET non-dominant morphology (n=63) and non-SET morphology (n=182) it was 59.7 and 44.7 months, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:240Received: 26.07.2021 Accepted: 25.01.2022 Correspondence: Alp USUBUTUN Department of Pathology, Hacettepe University School of Medicine, ANKARA, TURKEY E-mail: [email protected] Phone: +90 312 305 15 63 doi: 10.5146/tjpath.2022.01571Original Article (Turk Patoloji Derg 2022, 38:240-250) ABSTRACT Objective: High-grade serous ovarian carcinoma (HGSC) is one of the major tumors of the gynecological system with a poor survival rate and variable microscopic appearance.
📊
Key Findings & Data:Material and Method: We re-evaluated 305 HGSC ovarian resections morphologically and calculated the SET morphology percentages for each case.
💡
Conclusion & Impact:The median overall survival (OS) of ovarian carcinoma in SET-predominant tumors (n=60) was 81 months, while for tumors with SET non-dominant morphology (n=63) and non-SET morphology (n=182) it was 59.7 and 44.7 months, respectively.
🔬Design:Research Article
📍Scope:2021 Verileri
⚙️Variables:Domain Parameters

Abstract

240Received: 26.07.2021 Accepted: 25.01.2022 Correspondence: Alp USUBUTUN Department of Pathology, Hacettepe University School of Medicine, ANKARA, TURKEY E-mail: [email protected] Phone: +90 312 305 15 63 doi: 10.5146/tjpath.2022.01571Original Article (Turk Patoloji Derg 2022, 38:240-250) ABSTRACT Objective: High-grade serous ovarian carcinoma (HGSC) is one of the major tumors of the gynecological system with a poor survival rate and variable microscopic appearance. It was suggested that SET (solid, pseudo-endometrioid and transitional-like) morphology in ovarian HGSC is predictably associated with BRCA deficiencies. In this study, we investigated the microscopic patterns and some immunohistochemical markers predicting the prognosis of serous carcinoma. Material and Method: We re-evaluated 305 HGSC ovarian resections morphologically and calculated the SET morphology percentages for each case. Morphological and immunohistochemical data correlated with the survival and post-treatment disease progression data. Results: The median age at diagnosis was 57 years and the median follow-up period was 3.1 years. The median overall survival (OS) of ovarian carcinoma in SET-predominant tumors (n=60) was 81 months, while for tumors with SET non-dominant morphology (n=63) and non-SET morphology (n=182) it was 59.7 and 44.7 months, respectively. Conclusion: Predominant (more than 50%) SET morphology was significantly associated with increased survival rates of HGSC. Immunohistochemically, p53, ERCC1, ER, and PR antibodies were applied and only PR antibody positivity was found to be associated with borderline statistical significance for increased survival rates. Our results suggest that SET morphology may be a potential predictive and prognostic marker in managing the treatment strategies of HGSC.

🔖

Cite This Article

UNER, H., DEMIR, M., GOKSULUK, D., KARS, A., UNER, M., USUBUTUN, A. (2022). Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called “SET Morphology” and Progesterone Receptor Status. Türk Patoloji Dergisi, Cilt: 38 - Sayı: 3, 240–250. https://ajindex.com/articles/655198

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30
  2. WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020
  3. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009;4:287- 313
  4. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18:S19-32
  5. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994;73:1859-64
  6. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-6
  7. Sogaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand. 2006;85:93-105
  8. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-16
  9. Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015;39:287-93
  10. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625-36
  11. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B, National Israeli Study of Ovarian Cancer. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20:463-6
  12. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol. 2008;26:20-5
  13. Wiedemeyer WR, Beach JA, Karlan BY. Reversing p latinum resistance in high-g rade serous ovarian carcinoma: Targeting BRCA and the homologous recombination system. Front Oncol. 2014;4:34
  14. Bromley AB, Altman AD, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Han G, Kobel M. Architectural patterns of ovarian/pelvic high-grade serous carcinoma.